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ABSTRACT
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently 
the standard treatment for selected patients with peritoneal carcinomatosis of colorectal 
cancer. However, especially after incomplete cytoreduction, disease progression is 
common and this is likely due to limited tissue penetration and efficacy of intraperitoneal 
cytotoxic drugs. Tumor microenvironment-targeting drugs, such as VEGF(R) and PDGFR 
inhibitors, can lower the heightened interstitial fluid pressure in tumors, a barrier to 
drug delivery. Here, we investigated whether tumor microenvironment-targeting drugs 
enhance the effectiveness of intraperitoneal chemotherapy. A mouse xenograft model 
with two large peritoneal implants of colorectal cancer cells was developed to study 
drug distribution and tumor physiology during intraperitoneal Oxaliplatin perfusion. Mice 
were treated for six days with either Placebo, Imatinib (anti-PDGFR, daily), Bevacizumab 
(anti-VEGF, twice) or Pazopanib (anti-PDGFR, -VEGFR; daily) followed by intraperitoneal 
oxaliplatin chemotherapy. Bevacizumab and Pazopanib significantly lowered interstitial 
fluid pressure, increased Oxaliplatin penetration (assessed by laser ablation inductively 
coupled plasma mass spectrometry) and delayed tumor growth of peritoneal implants 
(assessed by MRI). Our findings suggest that VEGF(R)-inhibition may improve the efficacy 
of IPC, particularly for patients for whom a complete cytoreduction might not be feasible.
INTRODUCTION
Cytoreductive surgery with intraperitoneal 
chemotherapy (IPC) has been adopted by oncologic 
centers worldwide in the treatment of peritoneally 
metastasized cancer. Especially for colorectal and 
appendiceal carcinoma, the overall and disease-free 
survival of patients has improved with median overall 
survival reaching 33 and 130 months respectively [1, 2]. 
Nevertheless, the prognosis is still grave. Only a small 
fraction achieve five-year survival and those with an 
incomplete resection receive little benefit of this extensive 
procedure [3].
IPC utilizes a pharmacokinetic advantage conferred 
by the presence of the peritoneal-plasma barrier, 
which permits the use of high drug concentrations 
intraperitoneally whilst systemic absorption (and resulting 
toxicity) is limited [4]. Conversely, it may be assumed 
that the diffusion, tissue penetration, and cytotoxic effects 
are also limited. These aspects are mainly dependent 
on the molecular characteristics of each drug and the 
intraperitoneal pharmacokinetics have been described in 
previous research [5].
However, the delivery of intraperitoneal drugs 
is clearly also influenced by tumor type and its 
microenvironment. Most tumors feature a markedly 
Oncotarget29890www.impactjournals.com/oncotarget
raised interstitial fluid pressure (IFP) and this impedes the 
penetration and uptake of cytotoxic drugs [6]. Recently, 
experimental studies have demonstrated that reduction of 
the IFP by anti-VEGF(R) and/or -PDGFR therapy leads 
to improved delivery of systemic drugs [7]. The improved 
delivery combined with the disruptive effect on important 
tumor pathways may lead to synergistic, rather than 
additive, effects on tumor cell kill and growth delay. Thus 
far, it is unknown whether these effects could also enhance 
the efficacy of intraperitoneally administered drugs.
Here, we investigated whether pretreatment with 
anti-VEGF(R) and/or -PDGFR drugs enhances tumor 
penetration and increases efficacy of intraperitoneal 
Oxaliplatin perfusion in a mouse peritoneal carcinomatosis 
model. We present detailed results of intratumoral 
Oxaliplatin after IPC, pretreatment effect on tumor 
microenvironment and tumor growth delay.
RESULTS
Oxaliplatin inhibits HT29 cell growth in vitro 
and is comparatively more toxic in mice 
than in humans
To determine cancer cell line susceptibility to 
Oxaliplatin, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium) assay was performed (Figure 1A). 
The IC50 in HT29 cells after 1 h exposure was estimated 
at 0.343 mg/mL (95% CI 0.069 to 1.707 mg/mL). In vivo 
toxicity was evaluated by performing IPC with increasing 
doses of Oxaliplatin, starting at approximately 1/4th of 
the clinical dose (100 mg/m2) (Figure 1B, 1C). Major 
toxicity and weight loss were noted in mice receiving 
250 – 300 mg/m2 of Oxaliplatin and euthanasia was required. 
Necropsy uncovered no plausible surgical complications 
as the cause. At 200 mg/m2, initial dehydration, reduced 
activity, and food intake were noted. Weight loss 
and recuperation time were considered excessive. At 
150 mg/m2 and lower doses, no major toxicity was noted 
and mice recovered most lost weight within two weeks. 
The experiment was repeated at 150 mg/m2 in three mice 
with similar results. No further toxicity or mortality due to 
Oxaliplatin was observed during the experiment.
VEGF inhibition affects tumor IFP, oxygenation, 
and vascularity, but has no impact on size or 
proliferation index of HT29 xenografts
In the first experimental series, IPC was performed 
in mice with two large peritoneal tumor nodules after 
pretreatment with either Placebo, Imatinib, Pazopanib, 
or Bevacizumab (Figure 1D). Intraoperatively measured 
tumor IFP was significantly lower in the Bevacizumab 
and Pazopanib groups (Figure 2A, p = 0.0008). Imatinib 
did not differ from Placebo. All tumors had low values 
of oxygenation. However, the hypoxic fraction was 
Figure 1: Oxaliplatin IPC model and experiment timeline. A. Cell viability by MTT assay after application of different 
concentrations of Oxaliplatin with 1 h exposure (mean, standard deviation). B. Schematic representation of experimental set-up for 
Oxaliplatin IPC in mice. The perfusate flows through silicone tubing past a peristaltic roller pump and a heat exchanger. Temperature is 
recorded continuously and maintained around 37°C. Tumor IFP and oxygenation are monitored in vivo by intratumoral probes. C. Body 
weight decrease after Oxaliplatin IPC at increasing doses. IPC at 150 mg/m2 was repeated in three more mice to confirm the maximum 
tolerated dose. (Single values; 150 mg/m2: mean, standard deviation). D. Timeline of IPC experiments. The upper line shows the Oxaliplatin 
tumor penetration experiment with tumors resected immediately after IPC for LA-ICP-MS mapping. The lower line shows the tumor 
growth delay experiment in which mice underwent sequential MRI scans. N indicates the number of mice.
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significantly increased in the Bevacizumab group 
(Figure 2B, p = 0.0257). No statistical differences were 
detected between the other groups. No toxicity due to 
pretreatment was noted and mice appeared in good general 
condition.
Immediately after IPC, mice were euthanized 
and samples collected. Macroscopically, the tumors 
formed irregular large nodules averaging 124.85 mm3. 
No significant difference in size was found between the 
four groups (data not shown, p = 0.1656). Tumors grew 
Figure 2: In vivo tumor measurements. A. Intratumoral IFP relative to atmosphere (p = 0.0008, single values, median). * Placebo 
vs. Bevacizumab (p = 0.0028). *° Placebo vs. Pazopanib (p = 0.0407). B. Tumor hypoxic fraction (% < 5 mmHg pO2; p = 0.0257, single 
values, median). * Placebo vs. Bevacizumab (p = 0.0279).
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invasive in the muscular abdominal wall and formed 
nodules directed towards the peritoneal cavity. A few 
tumors broke through the external layers of the abdominal 
wall and showed partial invasion of the skin, but without 
ulceration. Rarely, adhesion to the bowel wall was noted. 
In the Bevacizumab group, some tumors contained small 
central hematomas.
On H&E staining (Figure 3A, 3B), tumor cells were 
invasive in the submesothelial and muscular layers of the 
peritoneal wall. The mesothelium was absent from the 
peritoneal tumor border in most samples, except around 
the edges, but mice fibroblasts were visible throughout the 
tumor. No inflammatory response (leukocyte infiltration) 
could be observed in the athymic mice model. However, 
some central necrosis was present in the larger tumors, 
particularly in the Bevacizumab and Pazopanib groups. 
The proliferation index (Ki-67) did not differ between 
treatment groups (Figure 3C, 3D; p = 0.1482). On 
CD105 / α-SMA slides, there was a significant difference 
in the microvascular density (Figure 4; p = 0.0323). 
Mice receiving Pazopanib had a lower average number 
of vessels per medium power field (CD105+, 200x, 
p = 0.0424) compared to Placebo. A similar trend was 
identified in the Bevacizumab group (p = 0.0780). Pericyte 
coverage analysis (% α-SMA+ vessels) did not reach 
significance (p = 0.2446) and values had a large variance. 
These findings suggest some vascular regression in the 
Bevacizumab and Pazopanib groups, with little indication 
of increased normalization.
Oxaliplatin concentration is greater in tumors 
with low IFP
With laser ablation inductively-coupled plasma mass 
spectrometry (LA-ICP-MS), color maps were created of 
the Platinum (Pt) and Phosphorus (P) distribution in tumor 
sections. These were then combined in Pt/P ratio maps to 
compare Pt concentration across samples. In the peritoneal 
border area (up to 1.68 mm), an increased Pt/P ratio was 
detected in tumors with a low IFP (Bevacizumab and 
Pazopanib) compared to those with a high IFP (Placebo 
and Imatinib) (Figure 5; p = 0.0221, n = 15). Differences 
in tumor centers could not be assessed because of irregular 
tumor shapes and sizes. In those sections containing both 
Figure 3: Microscopy overview and proliferation. A. H&E (100×). Overview of representative tumor section. Tumors were 
sectioned according to their orientation so that each section showed both the peritoneal and the muscular border. M indicates muscle 
and t tumor tissue. B. H&E (400×). Detail of tumor in which the mesothelium can still be identified along the peritoneal border (arrow). 
C. KI-67 (400×). Average hot spot of tumor cell proliferation. D. Proliferation index (% KI67+ nuclei; p = 0.1482, single values, median).
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normal tissue and tumor, the Pt maps showed a deeper 
penetration and a higher concentration of Pt in normal 
tissue compared to tumor.
Pretreatment with VEGF-inhibitors increases 
tumor growth delay after IPC
In the second experimental series, tumor growth 
delay was assessed on sequential MRI scans in four 
groups as described previously and with an added Sham 
(no Oxaliplatin) control group. Relative tumor growth 
differed significantly between groups (Figure 6A, 6B; 
p = 0.0006). Both Bevacizumab and Pazopanib groups 
had slower tumor growth than the Sham group, but only 
Bevacizumab reached statistical significance compared to 
Placebo. Tumor doubling time was Sham 9.157 (95% CI; 
6.687 to 14.52), Placebo 10.43 (95% CI; 8.123 to 14.56), 
Imatinib 10.75 (95% CI; 6.172 to 41.51), Bevacizumab 
14.90 (95% CI; 11.35 to 21.68), and Pazopanib 15.20 
days (95% CI; 10.28 to 29.18). Additionally, DCE-MRI 
was performed to assess tumor vascularity in vivo. Curve 
analysis of maximum uptake slope did not reach statistical 
significance (Figure 6D, 6E; p = 0.089). However, a trend 
could be observed of decreased values for the Bevacizumab 
and Pazopanib groups, corresponding to the IHC results.
DISCUSSION
Here, we demonstrate for the first time that 
anti-VEGF(R) treatment lowers IFP in peritoneal 
CRC xenografts, that this facilitates the diffusion and 
penetration of intraperitoneal Oxaliplatin, and that this 
results in greater tumor growth delay. Complications in 
this novel mouse IPC model were successfully managed 
by slightly reducing the Oxaliplatin dose to 150 mg/m2 and 
changing the perfusion fluid from glucose 5% to saline. 
While contrary to manufacturer’s instructions, several 
experimental and clinical reports confirm that Oxaliplatin 
is sufficiently stable for IPC in a chloride-containing 
solution when it is diluted shortly before perfusion [8, 9]. 
Oxaliplatin degrades into its active metabolite [Pt(dach)
Cl2] in the presence of chloride at a rate of less than 20% 
Figure 4: Tumor vascularity. A. α-SMA (brown) & CD105 (red) (200×). Representative image of MVD and Pericyte coverage of 
the Placebo and Imatinib groups. B. α-SMA & CD105 (200×). Representative image of the Bevacizumab and Pazopanib groups, mainly 
showing reduced vascularity. C. Microvascular density (CD105+ vessels; p = 0.0323, single values, median). * Placebo vs. Pazopanib 
(p = 0.0424). D. Pericyte coverage (% α-SMA+ vessels; p = 0.2446, single values, median).
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in 120 min. Notably, the large nodule mouse model in this 
study differs from most peritoneal carcinomatosis models 
(IP injection of cancer cells) in that specific size-dependent 
aspects of tumor biology such as oxygenation, perfusion, 
and IFP may be evaluated more accurately. The tumors 
are consistent in size, IFP, and macroscopic aspect with 
intraperitoneal nodules of human CRC (completeness 
of cytoreduction score CC-2) [10, 11]. Moreover, this 
model allows the use of advanced in vivo (intraoperative 
measurements, MRI) and ex vivo (LA-ICP-MS) techniques 
to be used.
LA-ICP-MS confirms the hypothesis that the uptake 
of Oxaliplatin in tumors is reduced compared to normal 
tissue and that by decreasing the IFP, the diffusion of 
Oxaliplatin can be improved. The IFP of normal tissue 
is reported as −1 to −3 mmHg and this supports the 
transcapillary exchange of solutes [12, 13]. In tumors, 
the high IFP impedes this transport and likewise also 
functions as a barrier to drug uptake for IPC [14]. Even 
though tumors are in direct contact with the cytotoxic 
solution, it is likely that only a minor part of the total drug 
dose reaches its target. For small molecules, the large 
surface area of the peritoneum assures a quick drug uptake 
mainly through healthy tissues into the portal and systemic 
circulation. The low IFP samples have more Oxaliplatin in 
the border region, but still very little in the tumor center. 
Previous attempts were made to increase cytotoxic drug 
uptake after IPC, mostly by changing IPC parameters such 
as temperature, perfusate or pressure [15]. Unfortunately, 
few of these studies analyzed tumor samples.
It is thought that antiangiogenic therapy transiently 
normalizes tumor vessels; e.g. decreases leakiness and 
IFP, prunes small abnormal vessels, and increases tissue 
perfusion as well as oxygenation [16]. However, this 
effect appears very dependent on dose and timing of 
therapy. Thus far, clinical evidence has been limited. 
Nevertheless, neoadjuvant Bevacizumab has been shown 
to normalize tumor vasculature in rectal cancer [17]. 
Here, both Bevacizumab and Pazopanib lower the IFP as 
expected, but more hypoxia is noted in the former group. 
Microvascular density is decreased, though pericyte 
coverage appears unaffected. DCE-MRI reveals a trend of 
Figure 5: Tumor oxaliplatin distribution. A. LA-ICP-MS color map of tumor P distribution (n = normal tissue, t = tumor). B. LA-
ICP-MS color map of tumor Pt (of Oxaliplatin) distribution (n = normal tissue, t = tumor). C. Pt/P maps of a tumor with high IFP (h) and 
one with low IFP (l). D. Average Pt/P intensity in the tumor peritoneal border region (p = 0.0221, single values, median).
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reduced maximum slope and this indicates antiangiogenic 
effect, but does not correspond directly with a single 
physiological parameter, rather it reflects a combination of 
vascular density and permeability [18]. Jain et al. describe 
the normalization window of antiangiogenic therapy 
as very brief; i.e. 6 days in mice and up to a month in 
man [16]. Furthermore, Tailor et al. state the possibility 
that normalization of oxygenation, perfusion or pressure 
are not necessarily concurrent [19]. These findings touch 
on the issue of continuous treatment with antiangiogenic 
therapy which is likely not ideal for every cancer and 
every drug. Research concerning optimal treatment 
windows could greatly impact current patient care [20].
Imatinib is unable to lower the IFP in HT29 
tumors and subsequently does not differ from Placebo 
in any of the tests. HT-29 lacks PDGFR, but is reported 
to express PDGF and to induce the expression of PDGF 
in neighboring stromal cells [21]. Unlike Bevacizumab, 
which is quite specific for human VEGF-A, Imatinib 
targets both human and mice PDGFRβ [22, 23]. 
PDGFRβ-inhibition is presumed to lower the IFP by 
reducing excessive matrix density caused by fibroblast 
proliferation and contractility [13]. Its role in vascular 
normalization is more ambiguous; both antiangiogenic 
effects and inhibition of pericytes have been reported. 
Pazopanib also targets PDGFR, but this activity cannot 
be separately evaluated from its VEGFR-inhibition in 
these experiments. Possibly, PDGF(R)-targeting drugs 
could be more successful in a different cancer model or 
treatment regimen [12, 13]. The PDGF(R) pathway plays 
an important role in the tumor microenvironment and 
should be included in future research [24].
Interestingly, Oxaliplatin itself barely affects tumor 
growth in our experimental model. LA-ICP-MS reveals 
only limited tumor penetration of Oxaliplatin. Conversely, 
Klaver et al. demonstrated a clear impact of hyperthermic 
IPC (HIPEC) on survival in rats, but this after complete 
cytoreduction [25]. Prodige 7 (NCT00769405), an 
ongoing randomized controlled trial, will hopefully 
provide an answer on whether the addition of HIPEC to 
cytoreductive surgery improves survival. Presumably, 
IPC affects only small nodules and free floating cancer 
Figure 6: Tumor growth delay and vascularity. A. Serial MRI images of mouse abdomen with bilateral tumor nodules (Placebo) 
as indicated by arrows. B. Serial MRI images (Bevacizumab). C. Relative tumor growth delay after IPC (exponential growth curves; 
p = 0.0006, mean, standard deviation). * Sham vs. Pazopanib (p < 0.05). *° Sham, Placebo vs. Bevacizumab (p < 0.05). D. Color 
overlay image of DCE-MRI analysis of maximum uptake slope. E. Tumor maximum uptake slope (p = 0.0890, single values, median).
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cells. Most clinical studies identify the completeness of 
cytoreduction as a clear prognostic indicator, with little 
benefit of cytoreductive surgery and HIPEC for patients 
with a suboptimal resection [3, 26]. Additional treatment 
such as neoadjuvant therapy, perhaps with VEGF(R)-
inhibition, may increase resectability and improve 
tumor susceptibility to IPC for this subgroup of patients. 
The increased growth delay we observed is likely a 
combination of increased Oxaliplatin cytotoxicity in the 
peritoneal border and antiangiogenic growth inhibition. 
However, VEGF(R)-inhibitors are usually not very 
effective on their own [27, 28]. Pretreatment does not 
decrease tumor size at the time of IPC and there is no 
change in cell proliferation, but some central necrosis is 
present. An alternative theory supporting the combination 
of cytotoxic and antiangiogenic drugs presumes that there 
may be enhanced retention of drugs by decreased vascular 
clearance, which could be useful for IP therapy [22].
Importantly, the morbidity of added antiangiogenic 
therapy cannot be evaluated in a xenograft experiment. 
Bevacizumab has previously been linked to surgical 
and non-surgical complications and is commonly 
discontinued in the weeks leading up to surgery (4–8 
weeks). Pazopanib may cause similar toxicity but has 
the advantage of a much shorter half-life (30.9 h). 
Nevertheless, several studies report that the possible 
additional morbidity of neoadjuvant VEGF(R)-inhibitors 
is not prohibitive, even for complex surgery [29, 30]. 
Moreover, Starlinger et al. demonstrated in a prospective 
trial that six weeks after therapy cessation, VEGF 
was still effectively blocked by Bevacizumab without 
hindering wound-healing [31].
There are some limitations to this study. First, no 
quantitative LA-ICP-MS mapping could be performed. 
Other methods that determine drug concentration in whole 
tissue samples would likely not have been sufficiently 
sensitive to detect the changes in Oxaliplatin penetration. 
Recent X-Ray Fluorescence pilot studies have successfully 
provided a detailed analysis in a similar experimental set-
up (unpublished results). Future clinical trials in this center 
will employ either quantitative LA-ICP-MS or X-Ray 
Fluorescence. Secondly, no pharmacokinetic models could 
be fitted to the DCE-MRI data mainly due to breathing-
related artefacts. Therefore, only semi-quantitative curve 
analysis was possible [18]. A different experimental set-up 
might reveal more therapy effect with DCE-MRI. Lastly, 
tumor samples could not be evaluated for cytotoxicity 
after IPC. For Oxaliplatin analysis, samples had to be 
resected immediately. Future experiments could examine 
tumors 24 to 72 h after IPC for the detection of apoptosis, 
DNA strand breaks, and Oxaliplatin-DNA adducts. To our 
knowledge, no antibody has been developed for the latter, 
but several exist for Cisplatin-DNA adducts [32].
In conclusion, our findings suggest that neoadjuvant 
therapy with VEGF(R)-inhibitors may improve the 
efficacy of IPC, especially for patients for whom a 
complete cytoreduction might not be feasible. It remains 
for clinical trials to determine optimal dosage and 
especially treatment window to achieve the desired 
effect. Likewise, morbidity should still be evaluated 
comprehensively.
MATERIALS AND METHODS
All animal experiments were approved by the Animal 
Ethics Committee of the Faculty of Medicine, Ghent 
University, and were performed according to Belgian and 
European legislature on animal welfare. Mice were fed 
ad libitum and kept under standard conditions. All proce-
dures were performed under general anesthesia (IsoFlo, 
Abbott, Belgium) and analgesia (Ketoprofen, 5 mg/kg; 
Buprenorphin, 0.05 mg/kg). Mice were evaluated daily 
for pain or discomfort and were given further analgesia up 
to two days post-operatively. All procedures on animals 
were performed in a laminated flow cabinet and standard 
cytotoxic drug safety precautions were applied.
Cancer cell line
HT-29, a human colon cancer cell-line, was obtained 
from the ATCC. The cells were cultured at 37°C in 5% 
CO2 humidified atmosphere in McCoy’s SA medium 
(Invitrogen, 26600-023) with Fungizone (Bristol Myers 
Squibb B.V, 3440 AM Woerden), 10% fetal bovine serum 
(Greiner Bio One, 758093), and penicillin-streptomycin 
(Invitrogen, 15070-063). The HT29 cells were 
authenticated by STR DNA profiling (ATCC, 25/02/14).
An MTT assay as described by De Smet et al. 
was performed to evaluate Oxaliplatin cytotoxicity 
in vitro [33]. Briefly, cells were seeded in 96-well plates 
at a concentration of 8 × 104 cells/ml. After 24 h, 20 μL 
medium is replaced by 20 μL of drug solution. Oxaliplatin 
concentrations of 100 μg/mL, 50 μg/mL, 20 μg/mL, 
10 μg/mL, 5 μg/mL, and 1 μg/mL were assessed. Eight 
wells per concentration were used and all experiments 
were repeated (3x). Next, the plates were incubated 
for 60 min at 37°C and 10% CO2. Then, the oxaliplatin 
solution was replaced by 200 μL fresh medium. 
Afterwards, the cells were incubated for 24 h at 37°C and 
10% CO2. Finally, the cytotoxicity of the formulations was 
evaluated via MTT assay and measured by assessing the 
optical density using an ELISA-plate reader (Paradigm 
Detection Platform, Beckman Coulter, Suarleé, Belgium).
Xenograft model
1.5 × 106 HT-29 cells suspended in 40 μL Matrigel 
(Corning BV, Amsterdam, the Netherlands) were 
injected subperitoneally in the right and left side of the 
anterolateral abdominal cavity of nude athymic mice 
(8 WO male Foxn1nu, Harlan, Horst, the Netherlands). 
The peritoneal layer covering the gelled nodules 
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was superficially incised to promote intraabdominal 
expansion (Supplementary Figure S1). The abdomen was 
closed in two layers with PDS 6/0 (Ethicon, Johnson & 
Johnson Intl., Brussels, Belgium).
Intraperitoneal chemotherapy procedure
The intraperitoneal perfusion circuit was cons-
tructed out of silicon tubing (Pumpsil®, Watson-Marlow, 
Zwijnaarde, Belgium), a peristaltic roller pump (520 
U, Watson-Marlow, Zwijnaarde, Belgium), and a heat 
exchanger (M3 Lauda, Lauda-Brinkman, NJ, USA) 
(Figure 1B). Anesthetized mice were placed on a 
heating pad and a midline laparotomy was performed. 
The edges of the abdominal wall were sutured with 
PDS 6/0 to a metal ring in a method similar to the open 
(coliseum) IPC technique. Oxaliplatin (100–300 mg/
m2) was added to 2 L/m2 saline (NaCl 0.9%) and briefly 
circulated and preheated in a closed circuit. Perforated 
inflow and outflow catheters with attached temperature 
probes were placed in the abdomen and the perfusate 
was then circulated for exactly 60 min. Temperature was 
continuously measured and registered by E-Val® 2.10 
Software (ELLAB®, Roedovre, Denmark). Perfusion 
rate and heat exchanger temperature were adjusted 
intermittently by small increments to maintain the intra-
abdominal temperature between 36°C and 38°C. Special 
care was taken to ensure that both tumor nodules were 
fully submerged and no perfusate was spilled. After 
60 min, the perfusate was evacuated by suction. The 
abdomen was closed in two layers with PDS 6/0.
Maximum tolerated dose
IPC with Oxaliplatin in increasing doses (100–300 
mg/m2) was performed in five mice. Mice received pain 
relief (see above) and were euthanized in case of clear 
morbidity. The starting dose was defined as 1/4th of that 
in humans relative to body surface area. The maximum 
tolerated dose (MTD) was defined as the highest non-
lethal dose without serious adverse effects (bodyweight 
decrease <10% after 2 weeks) [33]. IPC with the same 




Mice were divided into four groups of seven 
animals, each receiving a different pretreatment from day 
10 to 15 after HT29 implantation. The first group, Placebo, 
received either daily oral gavage of 0.15 mL PBS or IP 
injections of 0.15 mL saline solution on day 10 and 14. 
The second, Imatinib, received daily oral gavage of 50 mg/
kg Imatinib mesylate (Glivec®, Novartis; anti-PDGFR) in 
PBS. The third, Bevacizumab, was injected on day 10 
and 14 with 5 mg/kg Bevacizumab (Avastin®, Roche; 
anti-VEGF (human)). The fourth, Pazopanib, received 
daily oral gavage of 100 mg/kg Pazopanib hydrochloride 
(Votrient®, GSK; anti-VEGFR, -PDGFR) in distilled water 
(0.5% HMPC, 0.1% tween 80).
Intraperitoneal chemotherapy
IPC was performed on day 15 (after the last 
pretreatment dose) with 150 mg/m2 Oxaliplatin for 60′ 
at 36–38°C as described previously. Immediately after 
IPC, mice were euthanized by intracardiac puncture and 
exsanguination. Blood and perfusate were preserved. 
Left tumor nodules were excised and measured in three 
dimensions with electronic calipers.
Intraoperative measurements
Tumor IFP was measured using a fine (0.36 mm) 
glass fiber based on the Fabry Perot interferometer 
(Samba Preclin®, Samba Sensors, Bioseb, Vitrolles, 
France) according to the method described by Ozerdem 
[34]. Briefly, the probe is placed in a perforated 30-gauge 
catheter filled with gel (Duratears®, Alcon). The catheter is 
then carefully introduced along a premade needle track into 
the center of the right tumor nodule. Tumor IFP (relative 
to the atmosphere, mmHg) was recorded for 5 to 8′ 
after achieving a stable value.
Tumor oxygenation was measured throughout the 
nodule using a single fluorescence based fiberoptic pO2 
‘Bare-Fibre’ sensor (OxyLite®, Oxford Optronix, Oxford, 
UK) in a method similar to Ceelen et al [35]. In short, the 
probe was fixed to a micromanipulator and guided through 
the tumor along premade needle tracks. Measurements 
were made every 200 μm for up to 30 data points. 
Data was collected with Powerlab/8sp (ADInstruments, 
Oxford, UK) and the hypoxic fraction (% <5 mmHg pO2) 
was calculated.
Tumor samples and histology
Tumors were placed for 24 h in formaldehyde 4% 
and then conserved in PBS until processed and embedded 
in paraffin. Sample slices (5 μm) were cut by microtome 
for microscopic analysis (ColorView I, BX43F, Olympus, 
Tokyo, Japan). Standard H&E and Ki-67 staining were 
carried out for each tumor. Tumor regions were identified 
on H&E and visually analyzed for invasion, necrosis 
and uncommon features. Proliferation index (Ki-67) was 
assessed by hot spot analysis (up to 6/slide) and quantified 
using ImmunoRatio (Institute of Biomedical Technology, 
University of Tampere). Additionally, double IHC for 
α-SMA (pericytes) and CD105 (endothelial cells) was 
performed. In brief, tissue slices were deparaffinized 
in xylene, hydrated in ethanol and unmasked by citrate 
buffer pH 6 at 95°C for 20′. Endogenous peroxidase was 
blocked by 3% H2O2 in PBS and mouse IgG by M.O.M. 
basic kit (BMK-2202, Vector Lab.). Slides were incubated 
with α-SMA antibody (DAKO M0851, monoclonal 
mouse anti-human/rat) 1/200 in MOM diluent at room 
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temperature for 30′. MOM Biotinylated Anti-Mouse IgG 
reagent was applied for 10 min at room temperature. ABC 
kit (Vectastain Vector & PK-6100) was added and then 
stained with DAB. Afterwards, a blocking buffer (10% 
NRS, 1% BSA, and 0.2% Tween 20 in PBS) was applied 
for 1 h. Slides were incubated overnight with Ab goat 
anti-mouse Endoglin (CD105 R&D systems ref. AF1320) 
1/50 in PBS + 1/10 blocking buffer. LSAB+ System-AP 
kit (DAKO K0678) was used according to manufacturer’s 
instructions and Fuchsin+ chromogen was added for 1′ at 
room temperature. Finally, slides were counterstained with 
haematoxylin. Microvascular density (CD105+ vessels) 
and pericyte coverage (CD105+ & α-SMA+ vessels) were 
assessed by hot spot analysis (up to 6/slide) using Fiji [36].
Platinum measurements
A New Wave Research UP193HE ArF* excimer-
based laser ablation system (New Wave Research, CA, 
USA) coupled to an Element XR (Thermo Scientific, 
Braunschweig, Germany) double-focusing sector 
field ICP-MS instrument was used to determine the 
distribution of Pt within thin section of tissues (20 μm 
paraffinated slices). This LA-unit was equipped with a 
standard circular ablation cell with a diameter of 5 cm. 
Thin sections of tissue were scanned with a laser beam 
with a diameter of 80 μm. The scanning parameters were 
selected such as to provide square pixels in the final 
elemental map (80 × 80 μm). The material released from 
the surface of the sample upon ablation was transported 
using He as a carrier gas into the ICP ion source. Post-
ablation, the He flow carrying the dry sample aerosol was 
admixed with Ar prior to introduction into the ICP. Both 
laser beam diameter and laser repetition frequency have 
been selected carefully, taking into account the nature of 
the sample and the concentration of the target element. 
Also, the incident laser fluence has been optimized. 
Color maps were created of Pt and P distribution and 
of the Pt/P ratio. LA-ICP-MS settings are summarized 
in Supplementary Table S1. Pt/P maps were analyzed 
using Fiji by identifying the peritoneal border region 




Mice were divided into five groups of four animals. 
Four groups received pretreatment as described previously, 
while the fifth, Sham, received either daily oral gavage of 
0.15 mL PBS or IP injections of 0.15 mL saline solution 
on day 10 and 14, and underwent intraperitoneal perfusion 
with saline (without Oxaliplatin). IPC was performed as 
described previously on day 15 and mice were euthanized 
on day 28.
MR acquisition and image analysis
MR images were acquired at three time points (day 
14, 19, and 26) on a 7T system (Bruker PharmaScan 
70/16, Ettlingen, Germany) with a mouse body volume 
coil. Mice were anaesthetized with isoflurane (5% 
induction, 1.5% maintenance, 0.3 L/min) and warmed 
with a water-based heating blanket. Anatomical 
information was obtained with a T2-weighted sequence 
(TurboRARE) with the following parameters: TR 
3661 ms, TE 37.1 ms, 100 μm in-plane resolution, 30 
contiguous slices of 600 μm, and acquisition time 9′1”. 
Pre- and post-contrast T1-weighted images were obtained 
with a RARE sequence with parameters TR 1464 ms, 
TE 9.1 ms, 120 μm in-plane resolution, 30 contiguous 
slices of 600 μm, and acquisition time 4′17”. Dynamic 
contrast-enhanced MR images (DCE-MRI) were 
acquired for a single slice using a FLASH sequence with 
the following parameters: TR 12 ms, TE 3.4 ms, 268 μm 
in-plane resolution, 550 repetitions, temporal resolution 
1.344′’, and acquisition time 12′19”. The oblique slice 
was rotated such that both tumors were covered. The 
gadolinium-based contrast agent (Vistarem 50 mmol/kg, 
Guerbet, Villepinte, France) was intravenously injected 
1′ after start of the acquisition. Total acquisition time 
per session was 35′. Tumor volume was measured slice-
by-slice using Fiji by multiplying total surface area 
with voxel thickness (0.6 mm). Relative tumor volume 
was set as the measured volume divided by the initial 
volume (day 14). Dynamic time series were analyzed 
with MIStar version 3.2.62.03 (Apollo MIT, Melbourne, 
Australia) using curve analysis. ROI of tumors were 
manually selected and mean values were determined.
Statistical analysis
Statistical analysis was performed using Graphpad 
Prism 6 (Graphpad Software, Inc.; La Jolla, CA, USA). 
Data was analyzed using non-parametric tests (Mann-
Whitney-U, Kruskall-Wallis, Dunn’s method). Tumor 
growth delay and MTT IC50 were determined using non-
linear regression analysis (exponential growth and dose-
response inhibition). Alpha was set at 0.05 for all tests.
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